Medicare Study: Bevacizumab, Ranibizumab No Riskier Than Other AMD Therapies
Bevacizumab and ranibizumab did not increase risk of mortality, myocardial infarction, bleeding or stroke among patients with age-related macular degeneration when compared with photodynamic therapy or pegaptanib use, a study found.